Establishment of retroviral pseudotypes with influenza hemagglutinins from H1, H3, and H5 subtypes for sensitive and specific detection of neutralizing antibodies

Journal of Virological Methods

Volumn 153, Issue 2, 2008, Pages 111-119

  Wang, Wei ^a   Butler, Eboneé N ^b   Veguilla, Vic ^b   Vassell, Russell ^a   Terrig Thomas, J ^a   Moos Jr , Malcolm ^a   Ye, Zhiping ^a   Hancock, Kathy ^b   Weiss, Carol D ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

Hemagglutinin; Hemagglutinin inhibition; Influenza; Neutralization; Protease; Pseudotype

Indexed keywords

HEMAGGLUTININ; NEUTRALIZING ANTIBODY; PROTEIN SUBUNIT; PROTEINASE; TRYPSIN; VIRUS VECTOR;

ANTIBODY DETECTION; ARTICLE; DISEASE PREDISPOSITION; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOBLOTTING; INFLUENZA; INFLUENZA VIRUS A; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; RETROVIRUS; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALS; ANTIBODIES, VIRAL; CELL LINE; GENETIC VECTORS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; NEUTRALIZATION TESTS; RABBITS; RETROVIRIDAE; SENSITIVITY AND SPECIFICITY;

ORTHOMYXOVIRIDAE;

EID: 53049089447     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2008.07.015     Document Type: Article

References (37)

1. Baras B., Stittelaar K.J., Simon J.H., Thoolen R.J., Mossman S.P., Pistoor F.H., van Amerongen G., Wettendorff M.A., Hanon E., and Osterhaus A.D. Cross-protection against Lethal H5N1 challenge in Ferrets with an adjuvanted pandemic influenza vaccine. PLoS ONE 3 (2008) e1401
2. Barr P.J. Mammalian subtilisins: the long-sought dibasic processing endoproteases. Cell 66 (1991) 1-3
3. Bartosch B., Bukh J., Meunier J.C., Granier C., Engle R.E., Blackwelder W.C., Emerson S.U., Cosset F.L., and Purcell R.H. In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 14199-14204
4. Bottcher E., Matrosovich T., Beyerle M., Klenk H.D., Garten W., and Matrosovich M. Proteolytic activation of influenza viruses by serine proteases TMPRSS2 and HAT from human airway epithelium. J. Virol. 80 (2006) 9896-9898
5. Bright R.A., Carter D.M., Crevar C.J., Toapanta F.R., Steckbeck J.D., Cole K.S., Kumar N.M., Pushko P., Smith G., Tumpey T.M., and Ross T.M. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS ONE 3 (2008) e1501
6. Chen B.J., Leser G.P., Morita E., and Lamb R.A. Influenza virus hemagglutinin and neuraminidase, but not the matrix protein, are required for assembly and budding of plasmid-derived virus-like particles. J. Virol. 81 (2007) 7111-7123
7. Finer M.H., Dull T.J., Qin L., Farson D., and Roberts M.R. kat: a high-efficiency retroviral transduction system for primary human T lymphocytes. Blood 83 (1994) 43-50
8. Hatziioannou T., Valsesia-Wittmann S., Russell S.J., and Cosset F.L. Incorporation of fowl plague virus hemagglutinin into murine leukemia virus particles and analysis of the infectivity of the pseudotyped retroviruses. J. Virol. 72 (1998) 5313-5317
9. He Y., Manischewitz J., Meseda C.A., Merchlinsky M., Vassell R.A., Sirota L., Berkower I., Golding H., and Weiss C.D. Antibodies to the A27 protein of vaccinia virus neutralize and protect against infection but represent a minor component of Dryvax vaccine-induced immunity. J. Infect. Dis. 196 (2007) 1026-1032
10. Hsu M., Zhang J., Flint M., Logvinoff C., Cheng-Mayer C., Rice C.M., and McKeating J.A. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 7271-7276
11. Keck Z.Y., Li T.K., Xia J., Bartosch B., Cosset F.L., Dubuisson J., and Foung S.K. Analysis of a highly flexible conformational immunogenic domain a in hepatitis C virus E2. J. Virol. 79 (2005) 13199-13208
12. Kido H., Okumura Y., Yamada H., Le T.Q., and Yano M. Proteases essential for human influenza virus entry into cells and their inhibitors as potential therapeutic agents. Curr. Pharm. Des. 13 (2007) 405-414
13. Klenk H.D., Rott R., Orlich M., and Blodorn J. Activation of influenza A viruses by trypsin treatment. Virology 68 (1975) 426-439
14. Kobinger G.P., Limberis M.P., Somanathan S., Schumer G., Bell P., and Wilson J.M. Human immunodeficiency viral vector pseudotyped with the spike envelope of severe acute respiratory syndrome coronavirus transduces human airway epithelial cells and dendritic cells. Hum. Gene Ther. 18 (2007) 413-422
15. Kong W.P., Hood C., Yang Z.Y., Wei C.J., Xu L., Garcia-Sastre A., Tumpey T.M., and Nabel G.J. Protective immunity to lethal challenge of the 1918 pandemic influenza virus by vaccination. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 15987-15991
16. Lazarowitz S.G., and Choppin P.W. Enhancement of the infectivity of influenza A and B viruses by proteolytic cleavage of the hemagglutinin polypeptide. Virology 68 (1975) 440-454
17. McKay T., Patel M., Pickles R.J., Johnson L.G., and Olsen J.C. Influenza M2 envelope protein augments avian influenza hemagglutinin pseudotyping of lentiviral vectors. Gene Ther. 13 (2006) 715-724
18. Naldini L., Blomer U., Gallay P., Ory D., Mulligan R., Gage F.H., Verma I.M., and Trono D. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272 (1996) 263-267
19. Nefkens I., Garcia J.M., Ling C.S., Lagarde N., Nicholls J., Tang D.J., Peiris M., Buchy P., and Altmeyer R. Hemagglutinin pseudotyped lentiviral particles: characterization of a new method for avian H5N1 influenza sero-diagnosis. J. Clin. Virol. 39 (2007) 27-33
20. Netski D.M., Mosbruger T., Depla E., Maertens G., Ray S.C., Hamilton R.G., Roundtree S., Thomas D.L., McKeating J., and Cox A. Humoral immune response in acute hepatitis C virus infection. Clin. Infect. Dis. 41 (2005) 667-675
21. Rogers G.N., Paulson J.C., Daniels R.S., Skehel J.J., Wilson I.A., and Wiley D.C. Single amino acid substitutions in influenza haemagglutinin change receptor binding specificity. Nature 304 (1983) 76-78
22. Rowe T., Abernathy R.A., Hu-Primmer J., Thompson W.W., Lu X., Lim W., Fukuda K., Cox N.J., and Katz J.M. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J. Clin. Microbiol. 37 (1999) 937-943
23. Sandrin V., Boson B., Salmon P., Gay W., Negre D., Le Grand R., Trono D., and Cosset F.L. Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and nonhuman primates. Blood 100 (2002) 823-832
24. Seidah N.G., and Chretien M. Proprotein and prohormone convertases: a family of subtilases generating diverse bioactive polypeptides. Brain Res. 848 (1999) 45-62
25. Simmons C.P., Bernasconi N.L., Suguitan A.L., Mills K., Ward J.M., Chau N.V., Hien T.T., Sallusto F., Ha do Q., Farrar J., de Jong M.D., Lanzavecchia A., and Subbarao K. Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Med. 4 (2007) e178
26. Skehel J.J., and Wiley D.C. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu. Rev. Biochem. 69 (2000) 531-569
27. Steiner D.F., Smeekens S.P., Ohagi S., and Chan S.J. The new enzymology of precursor processing endoproteases. J. Biol. Chem. 267 (1992) 23435-23438
28. Steinhauer D.A. Role of hemagglutinin cleavage for the pathogenicity of influenza virus. Virology 258 (1999) 1-20
29. Temperton N.J., Chan P.K., Simmons G., Zambon M.C., Tedder R.S., Takeuchi Y., and Weiss R.A. Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes. Emerg. Infect. Dis. 11 (2005) 411-416
30. Temperton N.J., Hoschler K., Major D., Nicolson C., Manvell R., Hien V.M., Ha D.Q., Jong M.D., Zambon M., Takeuchi Y., and Weiss R.A. A sensitive retroviral pseodotype assay for influenza H5N1-neutralizing antibodies. Influenza Other Respir. Viruses 1 (2008) 105-112
31. Thomas J.T., and Moos Jr. M. Vg1 has specific processing requirements that restrict its action to body axis patterning centers. Dev. Biol. 310 (2007) 129-139
32. Thomas J.T., Prakash D., Weih K., and Moos Jr. M. CDMP1/GDF5 has specific processing requirements that restrict its action to joint surfaces. J. Biol. Chem. 281 (2006) 26725-26733
33. Wang W., Budhu A., Forgues M., and Wang X.W. Temporal and spatial control of nucleophosmin by the Ran-Crm1 complex in centrosome duplication. Nat. Cell Biol. 7 (2005) 823-830
34. Wharton S.A., Calder L.J., Ruigrok R.W., Skehel J.J., Steinhauer D.A., and Wiley D.C. Electron microscopy of antibody complexes of influenza virus haemagglutinin in the fusion pH conformation. EMBO J. 14 (1995) 240-246
35. WHO, 2003. Assays for Neutralizing Antibody to Influenza Viruses. Report of an informal scientific workshop, Dresden, March 18-19, 2003. Wkly. Epidemiol. Rec. 78, pp. 290-293.
36. Wu W.L., Chen Y., Wang P., Song W., Lau S.Y., Rayner J.M., Smith G.J., Webster R.G., Peiris J.S., Lin T., Xia N., Guan Y., and Chen H. Antigenic profile of avian H5N1 viruses in Asia from 2002 to 2007. J. Virol. 82 (2008) 1798-1807
37. Zufferey R., Nagy D., Mandel R.J., Naldini L., and Trono D. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat. Biotechnol. 15 (1997) 871-875